In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli
The rates of urinary tract infection with multidrug-resistant (MDR) Escherichia coli have dramatically increased and the treatment of these infections with single and double antibiotic combinations became limited or ineffective. The present study aimed at finding effective antibiotic combinations against MDR uropathogenic E. coli. Antibiotic susceptibility testing of uropathogenic E. coli isolates (n = 29) showed that all the examined isolates were found to be MDR. The interaction of double and triple combinations of fosfomycin (FOS) with imipenem (IPM), ciprofloxacin (CIP) and tobramycin (TOB) against selected isolates (n = 8) by checkerboard method showed that all the examined combinations exhibited synergistic effects (FIC index < 1) against tested isolate. However, 1/8, 5/8 and 6/8 of the isolates remained resistant to the constituent antibiotics in FOS/IPM, FOS/CIP and FOS/TOB combinations, respectively. Notably, the triple combinations (FOS/IPM/CIP, FOS/IPM/TOB and FOS/CIP/TOB) increased the synergism against all selected isolates at MIC levels lower than the susceptible breakpoints. Furthermore, time-kill analysis demonstrated that FOS/IPM combination exhibited synergistic and bactericidal effects with UTI-9. However, the combination had no effect on UTI-13. The highest synergistic and bactericidal effects against both representative isolates were achieved by FOS/IPM/CIP, FOS/IPM/TOB and FOS/CIP/TOB combinations after 2 h of post-treatment and lasted up to 24 h. Therefore, we report here that the combinations of FOS with IPM, CIP and TOB could be beneficial against MDR uropathogenic E. coli at least in vitro. The effectiveness of these antibiotics increased in combination with FOS compared to individual antibiotics acting alone.
This study was not funded.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Ramírez-Castillo FY, Moreno-Flores AC, Avelar-González FJ et al (2018) An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob 17:34. https://doi.org/10.1186/s12941-018-0286-5 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Rustini R, Jamsari J, Marlina M et al (2017) Antibacterial resistance pattern of Pseudomonas aeruginosa isolated from clinical samples at a General Hospital in Padang, West Sumatra, Indonesia. Asian J Pharm Clin Res 7:240–244Google Scholar
- 12.CLSI (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard-Ninth Edition. CLSI document M07-A9. 32:92Google Scholar
- 14.Giske CG, Martinez-Martinez L, Cantón R, et al (2013) EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, pp 1–40Google Scholar
- 15.Berenbaum MC (2018) A method for testing for synergy with any number of agents. 137:122–130Google Scholar
- 25.Samonis G, Maraki S, Karageorgopoulos DE et al (2012) Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31:695–701. https://doi.org/10.1007/s10096-011-1360-5 CrossRefPubMedGoogle Scholar
- 26.Evren E, Azap ÖK, Çolakoǧlu Ş, Arslan H (2013) In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 76:335–338. https://doi.org/10.1016/j.diagmicrobio.2013.04.004 CrossRefPubMedGoogle Scholar
- 29.Walsh CC, Landersdorfer CB, McIntosh MP et al (2016) Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother 71:2218–2229. https://doi.org/10.1093/jac/dkw115 CrossRefPubMedGoogle Scholar
- 31.Belley A, Neesham-Grenon E, Arhin FF et al (2008) Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 52:3820–3822. https://doi.org/10.1128/AAC.00361-08 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Sim JH, Jamaludin NS, Khoo CH et al (2014) In vitro antibacterial and time-kill evaluation of phosphanegold(I) dithiocarbamates, R3PAu[S2CN(iPr)CH2CH2OH] for R = Ph, Cy and Et, against a broad range of Gram-positive and Gram-negative bacteria. Gold Bull 47:225–236. https://doi.org/10.1007/s13404-014-0144-y CrossRefGoogle Scholar
- 33.Grégoire N, Raherison S, Grignon C et al (2010) Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:2379–2384. https://doi.org/10.1128/AAC.01478-08 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Skarzynski T, Mistry A, Wonacott A et al (1996) Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 4:1465–1474. https://doi.org/10.1016/S0969-2126(96)00153-0 CrossRefPubMedGoogle Scholar
- 37.Bensen DC, Rodriguez S, Nix J et al (2012) Structure of MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) from Vibrio fischeri in complex with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Acta Crystallogr Sect F 68:382–385. https://doi.org/10.1107/S1744309112006720 CrossRefGoogle Scholar
- 42.Okazaki M, Suzuki K, Asano N et al (2002) Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 8:37–42. https://doi.org/10.1007/s101560200004 CrossRefPubMedGoogle Scholar